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Abstract
Background: Pentosan polysulfate sodium (pentosan) is a semi-synthetic drug manufactured from beech-wood
hemicellulose by sulfate esterification of the xylopyranose hydroxyl groups. From in vitro and animal model studies,
pentosan has been proposed as a disease modifying osteoarthritis drug (DMOAD). The objective of this study was
to assess the efficacy, safety, and patient satisfaction in patients with mild radiographic knee osteoarthritis (OA)
findings and OA-associated symptoms and signs.
Methods: Twenty patients were assessed clinically at Nagasaki University Hospital. The radiographic indications of
OA were grade 1 to 3 using the Kellgren-Lawrence Grading System (K/L grade). Pentosan used in this study was
manufactured and supplied in sterile injectable vials (100 mg/ml) by bene GmbH, Munich, Germany. The study
was a single-center, open-label trial. Treatment consisted of 6 weekly subcutaneous injections (sc) of pentosan
(2 mg/kg). Patients were clinically assessed at entry and 1 to 8, 11, 15, 24 & 52 weeks post treatment. The results
were analyzed using one way ANOVA and Dunnett’s method.
Results: Hydrarthroses were reduced quickly in all cases. The clinical assessments, i.e., knee flexion, pain while
walking, pain after climbing up and down stairs, etc, were improved significantly and these clinical improvements
continued for almost one year. The dose used in this study affected the blood coagulation test, but was within
safe levels. Slightly abnormal findings were noted in serum triglycerides.
Conclusions: Pentosan treatment in twenty patients with mild knee OA seemed to provide improvements in
clinical assessments and C2C level of cartilage metabolism.
Trial Registration: UMIN Clinical Trials Registry (UMIN-CTR) UMIN000002790
Background
Osteoarthritis (OA) is the most widespread joint disease
affecting the elderly population [1]. Non-steroidal anti-
inflammatory drugs (NSAIDs), supplements of chon-
droitin sulfate and/or glycosaminoglycans are prescribed
as non-operative treatments. Recently, intraarticular
injection of hyaluronic acid (HA) has become a com-
mon treatment. Within the last few decades, the concept
of disease-modifying osteoarthritis drugs (DMOADs)
has been explored as an alternative therapeutic treat-
ment for OA.
From the results of previous in vitro and animal model
studies, we have proposed that the spectrum of pharmaco-
logical activities exhibited by pentosan polysulfate sodium
(pentosan) would qualify it as DMOADs. However, there
is little human clinical evidence to support this proposi-
tion. The aim of this study is to assess the clinical effec-
tiveness, functional outcome, safety, and patient
satisfaction of a series of subcutaneous injections of pento-
san in patients with symptomatic primary OA of the knee.
Parts of this study were presented at the International
Society of Orthopedic Surgery and Traumatology
(SICOT), in Hong Kong, China in 2008 and at the
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Methods
1. Study design
The clinical study was designed as a single-center, open-
label trial with an 8-week treatment phase. The radio-
graphic indications of OA were mild to moderate OA,
as described below. The follow-up continued for twelve
months.
2. Patient recruitment
Symptomatic patients with primary OA of the knee
were consulted by senior orthopedic surgeons who dis-
cussed their preferred management strategy. The radio-
graphic indications of OA were grades 1 to 3 using the
Kellgren-Lawrence Grading System (K/L grade) [2].
The elimination of patients was carried out according
to the following:
a. Patients who received previous intra-articular cor-
ticosteroid or another drug injection in the knee
joint within the previous 3 months.
b. Patients who had other lower-extremity musculos-
keletal disability or pain.
c. Patients who had pain exceeding 45 mm on a
100-mm visual analogue scale (VAS, 0- 100, 100 as
worst pain) immediately following walking for 50 m.
d. Patients who had any bleeding tendency with anti-
coagulant drugs (aspirin by way of exception) having
gastric or duodenal ulcer or with suspicion of ali-
mentary tract bleeding.
e. Patients who had other severe disease or handicap
(for example, diseases involving the liver, kidney,
and bone marrow).
f. Patients who had a past history of drug allergy.
g. Patients who were pregnant or were breastfeeding.
h. Patients who had difficulty providing us with
information.
i. Patients who had difficulty with the informed
consent.
About using NSAIDs, patients were not eliminated if
they underwent a two-week wash-out period before
entering into this study.
According to the above conditions, twenty patients
with knee OA were recruited.
The patient characteristics were as follows:
The average age was 63 years (from 35 to 80). All
cases were female. Eight cases had right knee OA, 12
had left knee OA. The classifications of the weight bear-
ing radiographs in K/L grade were grade 2 in 18 cases,
and grade 3 in 2 cases. The average WOMAC score at
the first visit was 37.0 (from 18 to 70).
3. Utilized agents
Pentosan polysulfate SP 54, used as pentosan in this
study, was manufactured and supplied in sterile inject-
able vials (100 mg/ml) by bene-Arzneimittel GmbH,
Munich, Germany.
It was illegal to use pentosan in Japan according to the
relevant Japanese laws. So the study was approved by
the review board of the Graduate School of Biomedical
Sciences, Nagasaki University.
4. Study Methods
Following consent, the treatment consisted of 6 weekly
subcutaneous injections (sc) of pentosan (2 mg/kg), fol-
lowing the two weeks of test injections (the first was
25 mg, the second was 50 mg).
No aspiration was performed, even if synovial fluid
was present in the knee. After the initial phase, all
patients were advised to avoid NSAIDs for 52 weeks.
Paracetamol (<2000 mg/day) was allowed for break-
through pain. All patients were allowed to maintain
standard physical therapy.
5. Outcome assessment
All patients were prospectively reviewed at entry and at
w e e k s1 ,2 ,3 ,4 ,8 ,1 2 ,1 6 ,2 4 ,a n d5 2w i t hi n i t i a lq u e s -
tion of pain at rest and walking, a physical examination
of the knee and VAS for pain with ROM exercises,
50 m walking, walking up and down stairs, or at 5 min-
utes rest after exercises. To check the change of the
metabolism in the cartilage, degradation of type II col-
lagen (C2C) in the blood was measured with a commer-
cial ELISA kit, in addition to the usual biochemical
tests. Weight bearing radiographs were reviewed at
baseline and at the end of study to grade the degree of
OA using K/L grade. WOMAC 3.1 (Likert) was used to
measure secondary effectiveness.
6. Adverse events
Safety was assessed at each visit. Pentosan is a heparin-
like agent and is not used in Japan. Activated clotting
time (ACT) is a measure of the anticoagulation affects
of heparin. So we checked the level of ACT, as well as
the usual blood coagulation test one hour after every
injection. All adverse events (AE), however minor, were
recorded.
7. Statistics
All data was handled by members who did not treat or
check the patients. The data was compared between the
entry point and each of the follow-up points. The statisti-
cal significance, compared with the value at entry, was
determined by one-way analysis of variance(ANOVA)and
Dunnett’s method. A p value of < 0.05 was considered sig-
nificant for all statistical tests. Comparison of data was
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Windows, ver. 5.0.1; SAS Institute Inc, Cary, NC, U.S.A.
Results
The trial began enrolling patients in November 2005
and finished in August 2007. All twenty patients were
followed up for one year.
1. Primary outcome measurements
The hydrarthroses were reduced quickly in all cases. The
ROM of the knee joint improved significantly (Figure 1,
Table 1). The clinical assessments, i.e., knee flexion, pain
while walking, pain after climbing up and down stairs (Fig-
ure 2, Table 1), and pain just after ROM exercise
improved significantly (table 1). The concentration of C2C
in the blood decreased significantly (Figure 3, Table 1).
The clinical benefits of this study continued for almost
one year. In the X-ray findings, neither improvement nor
degeneration were detected.
2. Secondary outcomes measurements
There was no statistical improvement in the total score of
the WOMAC compared to the baseline measurements
(Table 2). Both the WOMAC and the clinical assess-
ments showed the same tendencies in time course curve
(Figure 4). Pain while walking, as initial checks of each
visit at our clinic, showed statistical improvement com-
pared to the baseline measurements (Table 2).
3. Adverse events
The dose of pentosan affected the blood coagulation
tests, but the values were within a safe range. For aPPT,
the highest value was 61.7. For PT (INR), the highest
value was 1.47, which was weaker than the prophylactic
administration of cardiovascular event. The value of
ACT had the same tendency (Figure 5). Slightly abnor-
mal findings were noted in serum chemistry: i.e., serum
triglycerides at one hour after injection, but these were
reduced quickly in the follow-up period (Figure 6).
Six patients had a small amount of subcutaneous
bleeding at the injection site. Four patients claimed
severe pain at injection, but the pain decreased rapidly.
No patient suffered any major AE occurrence.
Discussion
OA is the most widespread joint disease affecting the
elderly population [1]. OA, by far the most common
form of arthritis, has a growing impact on health care.
Even now, there is no therapeutic agent that works
directly on OA. Various treatment guidelines published
by the American Academy of Orthopaedic Surgeons and
American College of Rheumatology recommend
Figure 1 Flexion angle of knee joint. The hydrarthroses were reduced quickly in all cases. The ROM of knee joint was improved significantly.
Clinical improvements were maintained at the one-year follow-up.
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paradigm, before and during non-selective NSAIDs and
cyclooxygenase-2 (COX-2) inhibitor therapy when those
therapies are contraindicated, are ineffective, or cause
adverse events [3-5]. Several drugs are candidates for
DMOADs. Kahan et al. recommended chondroitins 4
and 6 sulfate according to their international, rando-
mized, double-blind, placebo-controlled trial [6]. Henro-
tin recommended PIASCLEDINE®300 (Laboratories
Expansciences, Courbevoie, France) among avocado/soy-
bean unsaponifiables for his in vitro study and three
well-conducted, randomized, placebo-controlled, trials
[7,8]. However, further studies examining the method of
action of these compounds is needed [9].
Pentosan is a semi-synthetic drug manufactured from
European beech-wood hemicellulose by sulfate esterifi-
cation. Its molecular weight is from 4000 to 6000 Dal-
tons, and the average is 5700 Daltons. It was developed
as a heparin-like agent, which interferes with the bind-
ing of factor Xa to thrombin by an AT-III-independent
mechanism and has been used in Europe for conditions
such as thrombosis prophylaxis and the treatment of
phlebitis, for about fifty years. Pentosan is a very safe
drug and is the first and only oral medication that has
been approved by the US Food and Drug Administra-
tion for treating the pain or discomfort of interstitial
cystitis [10,11]. According to Ghosh, the functional
mechanism of pentosan for OA is as follows. In the car-
tilage, pentosan reduces cartilage degradation by directly
and indirectly affecting inflammatory mediators such as
MMP-3, IL-1 and TNF-alpha. Pentosan increased the
amount of proteoglycan incorporated into the extracel-
lular matrix. In the synovium, pentosan increases both
the synthesis and the molecular weight of hyaluronan.
In addition, pentosan has anti-inflammatory function
and strong fibrinolytic activity, which improves the
blood flow not only in the synovium but also in the sub-
chondral bone [12] In the veterinary field from 1996 to
date, there have been many studies and reports about
the use of pentosan for OA [13,14]. Pentosan is now
used worldwide. Ghosh and the Belgian study group
conducted four small human studies in 1990s for OA of
the knee, hip and fingers. In these studies, styles of med-
ication were one per os, one intraarticular injection and
Table 1 Primary outcomes
weeks 0 4 8 11 24 52
flexion angle Ave ± SD 132.2 ± 12.4 140.5 ± 8.03 142.9 ± 8.25 144.75 ± 7.41 144.35 ± 8.11 141.4 ± 7.74
% variation 0 5.8 7.61 9 8.7 6.5
*: p ‹ 0.05 * * * * *
VAS after 50 m walking Ave ± SD 27.7 ± 21.7 23.4 ± 16.4 16.5 ± 17.7 9.7 ± 14.3 9.8 ± 12.1 8.7 ± 12.2
% variation 0 -30.49 -53.5 -65.0 -66.67 -64.65
*: p ‹ 0.05
VAS after 5 min rest Ave ± SD 21.9 ± 21.3 18.8 ± 17.9 13.4 ± 16.1 8.8 ± 13.1 8.2 ± 13.7 8.1 ± 11.7
% variation 0 -14.4 -38.6 -60 -62.6 -63
*: p ‹ 0.05
VAS up & down stair walking Ave ± SD 41 ± 23.3 27.3 ± 16.2 18.6 ± 17.9 15.6 ± 17.2 12.8 ± 15.2 16.7 ± 17
% variation 0 -33.5 -54.6 -62 -68.7 -59.3
*: p ‹ 0.05 * * * *
VAS ROM exercise Ave ± SD 42.1 ± 25.4 29.3 ± 16.8 19.6 ± 17.8 13.0 ± 14.2 14.1 ± 15.8 14.9 ± 13.4
%variation 0 -30.49 -53.5 -69.3 -66.67 -64.65
*: p ‹ 0.05 * * * *
C2C Ave ± SD 39.7 ± 9.3 32.3 ± 11.7 31.4 ± 10.7 30.8 ± 9.8 31.9 ± 10.9
%variation 0 -18.64 -20.91 -22.41 -19.65
*: p ‹ 0.05 * *
The parameters were shown at entry point, 4
th,8
th,1 1
th,2 4
th,a n d5 2
nd weeks. They were provided as absolute levels, percentage of variation with time and
statistical significance. There were statistically significant improvements from the baseline score in flexion angle at 4
th,8
th,1 1
th,2 4
th,a n d5 2
nd weeks; in VAS up
and down stair walking and in VAS knee R.O.M. exercises at 8
th,1 1
th,2 4
th, and 52
nd weeks; and in C2C concentration in blood at 11
th and 24
th weeks. The
parameters, not limited to significant value, showed improvement in the percentage of variation with time. The improvement might appear in the late phase of
injection and continue to 52 weeks.
The asterisks indicate statistically significant improvement.
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Page 4 of 9Figure 2 Pain scores after climbing up and down stairs. Pain scores after climbing up and down stairs, measured by VAS, was improved
significantly. This improvement was maintained for almost one year.
Figure 3 Concentration of C2C in Blood. The concentration of C2C in the blood decreased significantly at 8 and 24 weeks. To check the
change of type II collagen metabolism, we measured C2C as a degradation marker of type II collagen, as C2C is said to be the only reliable
marker of cartilage metabolism. The significant decreasing tendency of C2C is thought to be more objective than those parameters measured
with VAS and ROM findings in this study.
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weeks 0 4 8 11 24 52
WOMAC total Ave ± SD 35.53 ± 15.03 39.75 ± 16.69 29.65 ± 20.4 23.4 ± 16.53 27.25 ± 19.68 26.74 ± 18.7
% variation 0 11.88 -16.55 -34.14 -23.3 -24.75
*: p ‹ 0.05
WOMAC pain Ave ± SD 3.47 ± 1.77 3.5 ± 1.47 2.45 ± 1.7 2.3 ± 1.3 2.4 ± 1.85 2.53 ± 1.43
% variation 0 0.95 -29.33 -33.66 -30.78 -27.13
*: p ‹ 0.05
Pain at rest Ave ± SD 14.85 ± 12.4 15.15 ± 8.03 14.15 ± 8.25 7.25 ± 7.41 6.85 ± 8.11 6.65 ± 7.74
% variation 0 2.02 -4.71 -51.18 -53.87 -55.22
*: p ‹ 0.05
Pain while walking Ave ± SD 32.1 ± 12.4 21.9 ± 8.03 18.5 ± 8.25 11.5 ± 7.41 11.8 ± 8.11 11.4 ± 7.74
% variation 0 -31.8 -42.5 -64.3 -63.4 -64.5
*: p ‹ 0.05 * * *
The parameters were shown at entry point, 4
th,8
th,1 1
th,2 4
th,a n d5 2
nd weeks. They were provided as absolute levels, percentage of variation with time and
statistical significance. The asterisks indicate statistically significant improvement.
There were significant differences in the values between individual follow-up points in the WOMAC scores, but there was no significant difference in the data
comparing the baseline and each follow-up. Pain when walking, as initial checks of each visit at our clinic, showed statistical improvement compared to the
baseline measurements at 11
th,2 4
th, and 52
nd weeks. These values showed remarkable improvement in percentage of variation with time.
Figure 4 WOMAC scores. There were significant differences in the values between individual follow-up points in the WOMAC scores, but there
was no significant difference in the data comparing the baseline and each follow-up. This may have been due to a problem with the baseline
evaluation or the techniques of the score system
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improvement in pain, mobility and synovial fluid condi-
tion [15]. The total dosage of pentosan in this study was
planned as 12 mg/kg according to Ghosh’s comments
and his reports [12,15].
To check the change of type II collagen metabolism,
we measured C2C as a degradation marker of type II
collagen, as C2C is said to be the only reliable marker
of cartilage metabolism [16]. The significant decreasing
tendency of C2C is thought to be more objective than
those parameters measured with VAS and ROM find-
ings in this study.
The symptoms and signs of early stage, i.e., improve-
ment of R.O.M., alleviation of hydrarthrosis and pain in
walking, could be attributed to the synovial improve-
ment by the anti-inflammatory action of pentosan. The
cartilage metabolism can be measured accurately, in
vivo, only by the degradation of collagen type II. In
recent years, it has been reported that pentosan interacts
with a disintegrin and metalloproteinase with thrombos-
pondin motifs (ADAMTS)-4 and ADAMTS-5, and pen-
tosan increased tissue inhibitor of metalloproteinase-3
(TIMP-3) [17-19]. The above improvements of aggrecan
might have occurred in this study and contributed to
the long-term improvement.
The pentosan study by Ghosh and many HA studies
had good WOMAC results [15,20-22]. In this study,
there were significant differences in the values between
individual follow-up points in the WOMAC scores, but
there was no significant difference in the data compar-
ing the baseline and each follow-up. This may have
been due to a problem with the baseline evaluation or
the techniques of the score system.
Lyon Schuss knee radiographs with definition of adequate
alignment of the medial tibial plateau might be useful, as no
improvement in X-ray findings could be detected in this
Figure 5 Activated Clotting Time (ACT) and Prothrombin Time (INR) 1 hour after injection.a :A C T ,b :P T( I N R ) .A c t i v a t e dc l o t t i n gt i m e
(ACT) is a measure of the anticoagulation affects of heparin. So we checked the level of ACT, as well as usual blood coagulation test one hour
after every injection. The dose of pentosan affected the ACT value, but the values were within a safe range. For PT (INR), the highest value was
1.47, which was weaker than the prophylactic administration of cardiovascular event.
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que, Eckstein reported that the quantitative magnetic reso-
nance imaging (qMRI) of cartilage morphology is a
promising tool for DMOAD development [24].
Also, the intraarthotic injection of hyaluronic acid is
said to have been proven safe and effective for OA. But
Raman reported that the incidence of local- and treat-
ment-related AE vary from l% to 8% [25]. As pentosan
is a subcutaneous injection administered far outside the
joint, while hyaluronic acid requires intraarticular injec-
tion, pentosan is considerably safer in this respect.
Furthermore, there are only very rare incidences of pen-
tosan AE according to the complete reference for the
Summary of Product Characteristics of Pentosan poly-
sulfate SP 54 [26]. Treatment with pentosan seems to be
considerably safer.
People rarely vary in their sensitivity to drugs, espe-
cially among Asian ethnicities, for example, gefitinib
tablets, for advanced non-small cell lung cancer, and
leflunomide, as DMARDs [27,28]. It is extremely impor-
tant that careful administration and observation be car-
ried out for new drugs.
Conclusions
This clinical treatment with pentosan for twenty knee
OA patients was considered as safe with only minor AE.
Improved clinical assessments were observed and degra-
dation of collagen type II was prevented with pentosan
treatment.
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Figure 6 Serum triglycerides 1 hour after injection. Slightly abnormal findings were noted in serum triglycerides at one hour after injection,
but this was reduced quickly in the follow-up period.
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